Acer Therapeutics Inc. (OTCPK: ACER)
Health Care · Pharmaceuticals · US
$—
— today · — 1Y
Acer Therapeutics Inc. (OTCPK: ACER) operates in the Pharmaceuticals industry within the Health Care sector.
Tweenvest scores Acer Therapeutics Inc. across four factors: quality 13/100. Its strongest factor is quality.
ACER price history
Not enough price history to draw a chart yet.
Key figures
- Market cap
- —
- Revenue (TTM)
- $371.79K
- P/E
- —
- EPS
- -2.23
- Dividend yield
- —
- Beta (5Y)
- —
- 52-week high
- $—
- 52-week low
- $—
- Avg volume (3M)
- —
- Shares outstanding
- —
- Employees
- 30
- Next earnings
- —
About Acer Therapeutics Inc.
Acer Therapeutics Inc. is a pharmaceutical company dedicated to acquiring, developing, and commercializing treatments for severe rare and life-threatening conditions. Its clinical-stage pipeline features four key candidates: EDSIVO, for vascular Ehlers-Danlos Syndrome in patients with a confirmed type III collagen mutation; ACER-001, a sodium phenylbutyrate formulation addressing inborn errors of metabolism such as urea cycle disorders and maple syrup urine disease; ACER-801 (osanetant), designed to manage induced Vasomotor Symptoms; and ACER-2820 (emetine), a host-directed therapy showing promise against various infectious diseases, including COVID-19. The company also collaborates with the National Center for Advancing Translational Sciences (NCATS) on developing emetine hydrochloride for COVID-19 and holds worldwide licensing rights for osanetant, a selective NK3 receptor antagonist, through an agreement with Sanofi. Established in 1991, Acer Therapeutics Inc. is headquartered in Newton, Massachusetts.
- ISIN
- US00444P1084
- Founded
- 1991
- Listed since
- Apr 14, 2004
- Exchange
- Pink Sheets LLC
- Currency
- USD
Other Pharmaceuticals companies
| Company | Market cap | Price | Day |
|---|---|---|---|
| Eli Lilly and CompanyNYSE: LLY | $1.12T | $1,255.40 | +0.88% |
| Johnson & JohnsonNYSE: JNJ | $651.25B | $270.24 | +1.07% |
| Merck & Co., Inc.NYSE: MRK | $376.37B | $152.55 | +2.39% |
| Roche Holding AGSWX: ROP | $373.91B | CHF375.60 | +1.02% |
| Novartis AGSWX: NOVN | $302.17B | CHF127.42 | +0.85% |
| AstraZeneca PLCLSE: AZN | $258.76B | £122.40 | +1.26% |
| Novo Nordisk A/SCPSE: NOVO B | $207.84B | Dkr300.85 | +1.59% |
| Pfizer Inc.NYSE: PFE | $159.99B | $28.07 | +1.01% |
Figures last refreshed Aug 18, 2026.